SIGY — Sigyn Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- $7.27m
- $8.99m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.143 | 0 | 0 | 0 | 0 |
Cost of Revenue | |||||
Gross Profit | 0.108 | — | — | — | — |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 3.4 | 0.916 | 2.54 | 2.15 | 2.46 |
Operating Profit | -3.26 | -0.916 | -2.54 | -2.15 | -2.46 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -3.31 | -1.26 | -3 | -2.93 | -4.15 |
Provision for Income Taxes | |||||
Net Income After Taxes | -3.31 | -1.26 | -3 | -2.93 | -4.15 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -3.07 | -1.26 | -3 | -2.93 | -4.15 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -3.07 | -1.26 | -3 | -2.93 | -4.15 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -42.3 | -6.85 | -2.71 | -3.13 | -3.77 |